Kura Oncology CCO Kirsten Flowers resigns; separation agreement provides 6 months salary + 2022 bonus

Kura Oncology, Inc.

Kirsten Flowers resigns as Chief Commercial Officer effective Jan 27, 2023.
Separation agreement provides 6 months base salary and 2022 annual cash bonus (discretionary).
Flowers agrees to a 6-month non-compete period following separation.
No successor named; search for replacement is ongoing.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Kirsten Flowers

Chief Commercial Officer

KURA · Kura Oncology, Inc.

Effective: 2023-01-27
Filed: January 13, 2023, 6:59 PM ET

On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Commercial Officer, effective as of January 27, 2023 (the “Separation Date”), in order to pursue other opportunities.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kirsten Flowers resigned as Chief Commercial Officer at Kura Oncology, Inc..

Action: resigned
Role: Chief Commercial Officer

Exact text from the filing

On January 10, 2023, Kirsten Flowers notified Kura Oncology, Inc. (the “Company”) of her intention to resign from her position as the Company’s Chief Commercial Officer, effective as of January 27, 2023 (the “Separation Date”), in order to pursue other opportunities.

View on SEC.gov

Kura Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-008358

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.